Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer (mPC).

368 Background: Multiple chemotherapy regimens are now available for the treatment of mPC. With these regimens median overall survival ranges between 6-11 months. Choice of regimen is often based on the patient’s performance status (PS) and toxicity profile of the regimen. Newer combinations may be associated with high financial costs. The objective of this study was to analyze the costs of first-line regimens to further aid in decision-making and develop a platform upon which to assess value. Methods: We calculated the monthly cost for individual standard regimens. These included gemcitabine (G), FOLFIRINOX (5-FU, irinotecan and oxaliplatin), and gemcitabine/nab-paclitaxel (GN-P). Furthermore, we evaluated other novel regimens. These included our institutional experience with dose-modified GN-P (dmG-NP) which will be presented at the ASCO GI conference. We additionally evaluated the cost of 3-weekly carboplatin/paclitaxel (CP) which formed the control arm of a phase II trial in mPC (NCT01280058). The res...